

Your Take: RELX

Q: How has your company adjusted its business model or invested in new, innovative projects in response to the pandemic?

A: In challenging times like these, the need for effective public-private collaboration has never been more important. One of our businesses, Elsevier, is a leading scientific and medical journal publisher and information analytics provider. Elsevier has partnered with the NIH and the WHO to support COVID research solutions, and has started up a [Novel Coronavirus Information Center](#), providing free access to Elsevier's research content, clinical insights and data analytics on this new disease. Our content has already been downloaded more than 50 million times. Every researcher on our platform could have a piece of the puzzle, a key to unlocking the solutions we need.

Q: During this time of uncertainty, what are the most pressing policy issues for your business?

A: Our priority remains the shared global priority: to help develop a cure or therapeutic to prevent or treat COVID-19. We are engaged on many fronts – both at Elsevier and in our data analytics and risk analysis work at LexisNexis. We are also working with governments to emphasize the need for substantial, ongoing government investment in education, training and scientific research. Across the company, we also are focused on the need for federal privacy legislation to empower and protect consumers, as well as reinforce responsible data practices, including around the prevention of waste, fraud, and abuse. Finally, COVID-19 is a major stress test for globalization. This crisis is a call to action for businesses, and governments, to recognize the enormous benefits of interconnection. By keeping our borders open for trade and the free flow of services, data and information, we are collectively working faster, and smarter, to address this global challenge.



DANNY MARTI

Head of Global Government Affairs, RELX

